Quick Dispatch:
Your glutathione lung cancer NRF2 supports non-small cell lung cancer growth independently of CBP/p300-enhanced glutathione synthesis | EMBO Reports orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your glutathione lung cancer NRF2 supports non-small cell lung cancer growth independently of CBP/p300-enhanced glutathione synthesis | EMBO Reports ships.
Need Help?
Questions about glutathione lung cancer NRF2 supports non-small cell lung cancer growth independently of CBP/p300-enhanced glutathione synthesis | EMBO Reports, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for glutathione lung cancer NRF2 supports non-small cell lung cancer growth independently of CBP/p300-enhanced glutathione synthesis | EMBO Reports in your area.
A study from the Birsoy lab showed that the antioxidant glutathione, when operating inside mitochondria, is a key factor enabling tumors to spread from the breast to the lung. #RockefellerScience #YearInReview
20.90
Role of Glutathione in Cancer: From Mechanisms to Therapies
29.63
Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer
22.81
Glutathione Depletion and Stalwart Anticancer Activity of Metallotherapeutics Inducing Programmed Cell Death: Opening a New Window for Cancer Therapy
26.88
A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer
23.61
Illustration of glutathione-responsive paclitaxel dimeric nanoparticles...
28.76
Involvement of glutathione peroxidases in the occurrence and development of breast cancers | Journal of Translational Medicine
26.13
